eligibility_summary
Eligible: age 15–80, life expectancy >6 mo, pathologically confirmed relapsed/refractory B‑cell NHL (report <3 yrs), ECOG 0–2, ≥1 measurable CT lesion ≥1.5 cm, contraception, consent. Exclude: CNS/bone marrow lymphoma, PB NK<5%/culture failure, other cancers, active infection or recent fever, HIV/TP+, serious organ/psychiatric disease, autoimmune/immunodeficiency, severe thrombocytopenia/platelet disorder, prior organ or allo‑SCT, pregnant/lactating, unable to communicate, per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1/2, single-arm trial in relapsed/refractory B‑cell NHL testing R‑GemOx (rituximab + gemcitabine + oxaliplatin) combined with autologous NK-cell infusions. Interventions/mechanisms: Rituximab (anti‑CD20 monoclonal antibody) tags B cells and drives ADCC, Gemcitabine (antimetabolite nucleoside analog) inhibits DNA synthesis, Oxaliplatin (platinum cytotoxic/alkylating-like) forms DNA crosslinks, Autologous expanded NK cells (cell therapy) provide innate cytotoxicity (perforin/granzyme) and enhance rituximab‑mediated ADCC via CD16. Targets/pathways: CD20+ malignant B cells, NK-cell activation (CD16/FcγRIII, NKG2D, NKp30/44/46), tumor DNA replication and crosslink repair pathways. NK dose: BSA×(2–4)×10^9 every 14 days. Primary endpoint: ORR.